Related Experiment Videos
[Blocking antibodies in Dermatophagoides allergy]
A Sánchez Armengol1, J Castillo Gómez, F Ortega Ruiz
1Servicio de Neumología, Hospital Universitario Virgen del Rocío, Sevilla.
Allergologia Et Immunopathologia
|November 1, 1995
Summary
Specific immunotherapy for Dermatophagoides allergy increased blocking antibody levels but showed limited clinical improvement. Nasal symptoms improved more in the immunotherapy group compared to conventional treatment alone.
Area of Science:
- Immunology
- Allergology
- Clinical Research
Background:
- Dermatophagoides allergy is a common condition.
- Understanding blocking antibody behavior during desensitization is crucial for treatment efficacy.
Purpose of the Study:
- To analyze blocking antibody (total IgG, IgG1, IgG4) levels against Dermatophagoides allergen extracts (CE, Der pI, Der pII).
- To correlate antibody levels with clinical outcomes in patients undergoing desensitizing treatment.
Main Methods:
- A cohort of 36 patients with Dermatophagoides allergy was studied.
- Patients received either specific immunotherapy (IT) plus conventional treatment or conventional treatment alone.
- Clinical symptoms (symptom score) and IgG subclass levels were monitored over 12 months.
Main Results:
- Patients receiving IT showed a subjective increase in all IgG subclasses, while the control group did not.
- No significant improvement in ocular or pulmonary symptoms was observed in either group.
- Nasal symptoms demonstrated a more favorable outcome in the IT group.
Conclusions:
- Specific immunotherapy for Dermatophagoides allergy leads to increased levels of blocking antibodies.
- While overall clinical improvement was limited, immunotherapy showed a trend towards better nasal symptom control.